Selzentry Panel Review Must Address Conflicting Data On Efficacy For Treatment-Naïve Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
As Pfizer readies itself for the upcoming advisory committee review, the company has new data backing Selzentry's use in the expanded population.